» Articles » PMID: 32149152

Hypoglycemia During Short-Term Intensive Insulin Therapy and Its Association with Long-Term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes

Overview
Journal J Diabetes Res
Publisher Wiley
Specialty Endocrinology
Date 2020 Mar 10
PMID 32149152
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Short-term intensive insulin therapy induces long-term glycemic remission in half of patients with newly diagnosed type 2 diabetes. The concomitant hypoglycemia needs further analysis.

Methods: We collected data from three randomized trials conducted with the same inclusion and exclusion criteria at our institution from 2002 to 2015. Continuous subcutaneous insulin infusion (CSII) was provided to achieve the glycemic goals within a week and then maintained for 14 days. Hypoglycemia episodes during short-term treatment and the one-year drug-free glycemic remission were observed.

Results: A total of 244 patients were included. The per day episode of mild hypoglycemia (3.0-3.9 mmol/L) was higher in the remission group than in the nonremission group (0.26 ± 0.20 vs. 0.18 ± 0.21, = 0.005). However, a moderate hypoglycemia episode (<3.0 mmol/L) per day was insignificantly lower in the remission group (0.02 ± 0.04 vs. 0.03 ± 0.04, = 0.005). However, a moderate hypoglycemia episode (<3.0 mmol/L) per day was insignificantly lower in the remission group (0.02 ± 0.04 vs. 0.03 ± 0.04, = 0.005). However, a moderate hypoglycemia episode (<3.0 mmol/L) per day was insignificantly lower in the remission group (0.02 ± 0.04 vs. 0.03 ± 0.04, = 0.005). However, a moderate hypoglycemia episode (<3.0 mmol/L) per day was insignificantly lower in the remission group (0.02 ± 0.04 vs. 0.03 ± 0.04.

Conclusions: Mild hypoglycemic episodes during the continuing insulin dose reduction period indicate a long-term drug-free euglycemic remission in patients with newly diagnosed type 2 diabetes. However, the insulin dosage should be reduced even more quickly in the future treatment to decrease the potential harms.

Citing Articles

Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type 1 and Patients with Type 2 Diabetes in China.

Zhao X, Ming J, Qu S, Li H, Wu J, Ji L Diabetes Ther. 2021; 12(12):3079-3092.

PMID: 34689295 PMC: 8586326. DOI: 10.1007/s13300-021-01166-z.


Development and Validation of a Hypoglycemia Risk Model for Intensive Insulin Therapy in Patients with Type 2 Diabetes.

Hu X, Xu W, Lin S, Zhang C, Ling C, Chen M J Diabetes Res. 2020; 2020:7292108.

PMID: 33015194 PMC: 7525304. DOI: 10.1155/2020/7292108.

References
1.
Mastaitis J, Wurmbach E, Cheng H, Sealfon S, Mobbs C . Acute induction of gene expression in brain and liver by insulin-induced hypoglycemia. Diabetes. 2005; 54(4):952-8. DOI: 10.2337/diabetes.54.4.952. View

2.
Puente E, Silverstein J, Bree A, Musikantow D, Wozniak D, Maloney S . Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction induced by severe hypoglycemia. Diabetes. 2010; 59(4):1055-62. PMC: 2844814. DOI: 10.2337/db09-1495. View

3.
Cryer P, Davis S, Shamoon H . Hypoglycemia in diabetes. Diabetes Care. 2003; 26(6):1902-12. DOI: 10.2337/diacare.26.6.1902. View

4.
Soydan N, Bretzel R, Fischer B, Wagenlehner F, Pilatz A, Linn T . Reduced capacity of heart rate regulation in response to mild hypoglycemia induced by glibenclamide and physical exercise in type 2 diabetes. Metabolism. 2013; 62(5):717-24. DOI: 10.1016/j.metabol.2012.12.003. View

5.
Dor Y, Glaser B . β-cell dedifferentiation and type 2 diabetes. N Engl J Med. 2013; 368(6):572-3. DOI: 10.1056/NEJMcibr1214034. View